Form 4: Avalo Therapeutics Director Gilla Kaplan Acquires Shares Through Restricted Stock Unit Vesting

Director Gilla Kaplan acquired 3,167 shares of Avalo Therapeutics common stock through the vesting of restricted stock units on March 28, 2025.

Summary

• On March 28, 2025, Gilla Kaplan, a director of Avalo Therapeutics, acquired 3,167 shares of common stock.
• This acquisition resulted from the vesting of restricted stock units (RSUs).
• The RSUs were granted on August 13, 2024, and vest in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027.
• Following the transaction, Kaplan directly owns 6,333 shares of Avalo Therapeutics common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine transaction related to previously granted equity compensation.

Positives

• The vesting of RSUs indicates continued service and commitment of the director to the company.

Industry Context

This is a standard Form 4 filing, reflecting a common practice of equity compensation for directors and officers in publicly traded companies.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's long-term performance.

Key Dates

Keywords

Avalo Therapeutics, Director, Gilla Kaplan, Restricted Stock Units, RSU, Beneficial Ownership, Form 4, AVTX, Vesting